ZA200801108B - Quinoline derivatives as antibacterial agents - Google Patents

Quinoline derivatives as antibacterial agents

Info

Publication number
ZA200801108B
ZA200801108B ZA200801108A ZA200801108A ZA200801108B ZA 200801108 B ZA200801108 B ZA 200801108B ZA 200801108 A ZA200801108 A ZA 200801108A ZA 200801108 A ZA200801108 A ZA 200801108A ZA 200801108 B ZA200801108 B ZA 200801108B
Authority
ZA
South Africa
Prior art keywords
antibacterial agents
quinoline derivatives
quinoline
derivatives
antibacterial
Prior art date
Application number
ZA200801108A
Other languages
English (en)
Inventor
Koenraad Jozef Marcel Andries
Jerome Emile Georges Guillemont
David Francis Alain Lancois
Koul Anil
Elisabeth Therese Jeanne Pasquier
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35768940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200801108(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA200801108B publication Critical patent/ZA200801108B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200801108A 2005-08-03 2008-02-01 Quinoline derivatives as antibacterial agents ZA200801108B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05107159 2005-08-03

Publications (1)

Publication Number Publication Date
ZA200801108B true ZA200801108B (en) 2009-05-27

Family

ID=35768940

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200801108A ZA200801108B (en) 2005-08-03 2008-02-01 Quinoline derivatives as antibacterial agents

Country Status (29)

Country Link
US (1) US8017606B2 (da)
EP (1) EP1912647B1 (da)
JP (1) JP5410753B2 (da)
KR (1) KR101337237B1 (da)
CN (1) CN101277695B (da)
AR (1) AR054889A1 (da)
AU (1) AU2006274879B2 (da)
BR (1) BRPI0614524B8 (da)
CA (1) CA2615901C (da)
CY (1) CY1114908T1 (da)
DK (1) DK1912647T3 (da)
EA (1) EA014832B1 (da)
ES (1) ES2437575T3 (da)
HK (1) HK1124233A1 (da)
HR (1) HRP20131116T1 (da)
IL (1) IL189141A (da)
JO (1) JO2952B1 (da)
MX (1) MX2008001602A (da)
MY (1) MY148241A (da)
NO (1) NO341247B1 (da)
NZ (1) NZ565283A (da)
PL (1) PL1912647T3 (da)
PT (1) PT1912647E (da)
RS (1) RS53065B (da)
SI (1) SI1912647T1 (da)
TW (1) TWI381839B (da)
UA (1) UA95916C2 (da)
WO (1) WO2007014940A2 (da)
ZA (1) ZA200801108B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1909907B (zh) * 2004-01-23 2010-06-23 詹森药业有限公司 喹啉衍生物及其在制备分枝杆菌抑制剂中的用途
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
WO2009091324A1 (en) * 2008-01-14 2009-07-23 Jyoti Chattopadhyaya Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivates as anti-mycobacterial agents
JP5246715B2 (ja) 2009-01-27 2013-07-24 独立行政法人科学技術振興機構 蛋白質架橋阻害剤およびその用途
WO2010144102A1 (en) * 2009-06-09 2010-12-16 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Material Command Pentafluorosulfanyl analogs of mefloquine
AU2013254674B2 (en) 2012-04-27 2017-02-02 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
US9617244B2 (en) 2012-04-27 2017-04-11 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
WO2014062658A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
EP2909189B8 (en) 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Heteroaryl linked quinolinyl modulators of ror-gamma-t
EP2909193B1 (en) 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Phenyl linked quinolinyl modulators of ror-gamma-t
US9642858B2 (en) 2012-10-30 2017-05-09 University of Pittsburgh—of the Commonwealth System of Higher Education Use of resazurin, or analogs thereof, for antibacterial therapy
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
AU2014334616A1 (en) 2013-10-15 2016-04-28 Janssen Pharmaceutica Nv Quinolinyl modulators of RORyt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
WO2015057206A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv SECONDARY ALCOHOL QUINOLINYL MODULATORS OF RORyt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9346782B2 (en) 2013-10-15 2016-05-24 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
GB201904796D0 (en) * 2019-04-04 2019-05-22 Univ Sheffield Antimicrobial agent
AR121682A1 (es) * 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
AR121683A1 (es) * 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317491D0 (en) * 1993-08-23 1993-10-06 Fujisawa Pharmaceutical Co New compound and a process for preparation thereof
US6376670B1 (en) * 1997-06-19 2002-04-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
GB9914486D0 (en) * 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917408D0 (en) * 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB0101577D0 (en) * 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
AR040336A1 (es) * 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
EP1527050B1 (en) * 2002-07-25 2010-04-07 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
DE50312598D1 (de) * 2002-10-10 2010-05-20 Morphochem Ag Komb Chemie Neue verbindungen mit antibakterieller aktivität
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
BRPI0416817A (pt) * 2003-11-20 2007-03-06 Janssen Pharmaceutica Nv 2-quinolinonas e 2-quinoxalinonas 7-fenilalquila substituìdas como inibidores da poli(adp-ribose)polimerase
EA010488B1 (ru) * 2003-12-05 2008-10-30 Янссен Фармацевтика Н.В. 6-замещённые 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли (адф-рибоза) полимеразы
CN1909907B (zh) * 2004-01-23 2010-06-23 詹森药业有限公司 喹啉衍生物及其在制备分枝杆菌抑制剂中的用途
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents

Also Published As

Publication number Publication date
AU2006274879A1 (en) 2007-02-08
CN101277695B (zh) 2011-12-14
CA2615901C (en) 2014-06-03
RS53065B (en) 2014-04-30
BRPI0614524B8 (pt) 2021-05-25
ES2437575T3 (es) 2014-01-13
EP1912647A2 (en) 2008-04-23
US20080255116A1 (en) 2008-10-16
BRPI0614524A2 (pt) 2011-04-05
NO341247B1 (no) 2017-09-25
CY1114908T1 (el) 2016-12-14
WO2007014940A8 (en) 2007-07-05
IL189141A0 (en) 2008-08-07
WO2007014940A2 (en) 2007-02-08
CN101277695A (zh) 2008-10-01
US8017606B2 (en) 2011-09-13
UA95916C2 (ru) 2011-09-26
JP5410753B2 (ja) 2014-02-05
CA2615901A1 (en) 2007-02-08
WO2007014940A3 (en) 2007-03-29
MY148241A (en) 2013-03-29
EA014832B1 (ru) 2011-02-28
HK1124233A1 (en) 2009-07-10
AU2006274879B2 (en) 2013-01-10
MX2008001602A (es) 2008-02-19
NZ565283A (en) 2011-07-29
IL189141A (en) 2015-10-29
SI1912647T1 (sl) 2014-01-31
AR054889A1 (es) 2007-07-25
EA200800501A1 (ru) 2008-10-30
JO2952B1 (en) 2016-03-15
KR101337237B1 (ko) 2013-12-06
TW200744594A (en) 2007-12-16
HRP20131116T1 (hr) 2013-12-20
KR20080038380A (ko) 2008-05-06
JP2009503024A (ja) 2009-01-29
PL1912647T3 (pl) 2014-02-28
PT1912647E (pt) 2013-12-05
TWI381839B (zh) 2013-01-11
NO20080955L (no) 2008-02-25
EP1912647B1 (en) 2013-09-11
DK1912647T3 (da) 2013-12-02
BRPI0614524B1 (pt) 2020-05-19

Similar Documents

Publication Publication Date Title
IL189141A0 (en) Quinoline derivatives as antibacterial agents
AP2654A (en) Quinoline derivatives as antibacterial agents
SG165348A1 (en) Quinoline derivatives as antibacterial agents
HK1120732A1 (en) Quinoline derivatives as antibacterial agents
HK1124232A1 (en) Quinoline derivatives as antibacterial agents
HK1122730A1 (en) Quinoline derivatives as antibacterial agents
HK1120734A1 (en) Quinoline derivatives as antibacterial agents
ZA200710698B (en) Quinoline derivatives as antibacterial agents